Skip to main content
. Author manuscript; available in PMC: 2018 Jan 15.
Published in final edited form as: Cancer Res. 2016 Oct 13;77(2):520–531. doi: 10.1158/0008-5472.CAN-16-1140

Figure 2. Rapamycin treats EL4 independent of interferon-γ, γδ T cells or adaptive immunity.

Figure 2

(A–C) IFN-γ KO, δ TCR KO, Rag2 KO and WT male mice (N=8–10/group) were challenged s.c. with 40,000 EL4 cells. Rapamycin 8 mg/kg or vehicle control, starting on day 4, was given on 5 consecutive days/week until the day before sacrifice. P values, two-way ANOVA. WT male mice were treated as above to determine prevalence and numbers of CD44hiCD62L− cells in (D) tumor draining lymph nodes (TDLN) among CD4+ or CD8+ T cells and (E) CD3+ T cells (GFP−Vβ12− cells) within tumors. N= 6/group in D–E. P values, unpaired t test. Error bars, mean ± SEM. KO, knockout.